Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 2
ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 p…
Non-muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
Estimated
~$10 – $7,500
John SfakianosNCT06503614
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With Bacillus Calmete-Guerin
The purpose of this study is to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Gueri…
Non-Muscle Invasive Bladder Cancer
Estimated
~$10 – $750
Johns Hopkins UniversityNCT05672615
Phase 1
Phase I Study Evaluating the Safety and Tolerability of Locally Administered Anti-CD40 Agonist Antibody (2141-V11) in Subjects With Bladder Cancer
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have t…
Non-muscle Invasive Bladder Cancer
Estimated
~$10 – $6,250
Memorial Sloan Kettering Cancer CenterNCT05126472
Observational
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less…
Non-muscle Invasive Bladder Cancer (NMIBC)
Estimated
~$10 – $6,250
Lahey ClinicNCT07187063